Aditxt, Inc. Files 8-K Amendment
Ticker: ADTX · Form: 8-K/A · Filed: Nov 21, 2024 · CIK: 1726711
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Aditxt filed an amendment to its 8-K, updating financial statements from April 1, 2024.
AI Summary
Aditxt, Inc. filed an amendment (Amendment No. 3) to its Form 8-K on November 21, 2024, reporting events that occurred on April 1, 2024. The filing pertains to financial statements and exhibits, with the company previously known as Aditx Therapeutics, Inc. and ADiTx Therapeutics, Inc.
Why It Matters
This amendment clarifies and supplements previous filings, providing updated information on Aditxt, Inc.'s financial statements and exhibits as of April 1, 2024.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, not indicating new material events or significant financial changes.
Key Players & Entities
- Aditxt, Inc. (company) — Registrant
- Aditx Therapeutics, Inc. (company) — Former company name
- ADiTx Therapeutics, Inc. (company) — Former company name
- April 1, 2024 (date) — Date of earliest event reported
- November 21, 2024 (date) — Filing date
FAQ
What is the purpose of this 8-K/A filing?
This filing is Amendment No. 3 to Aditxt, Inc.'s Form 8-K, intended to amend and supplement the original report concerning financial statements and exhibits.
What was the original report date for the events discussed in this amendment?
The earliest event reported in this amendment occurred on April 1, 2024.
What are the former names of Aditxt, Inc. mentioned in the filing?
The filing mentions Aditxt, Inc. was formerly known as Aditx Therapeutics, Inc. and ADiTx Therapeutics, Inc.
When was this amendment filed with the SEC?
This amendment was filed on November 21, 2024.
What specific items are being amended or supplemented in this filing?
The filing specifically pertains to Financial Statements and Exhibits.
Filing Stats: 1,816 words · 7 min read · ~6 pages · Grade level 14.9 · Accepted 2024-11-21 16:15:10
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 ADTX The Nasdaq Stock Market LLC
- $115,000 — iii) Adivir shall pay Appili the sum of $115,000 no later than 5:00 p.m. (ET) on Novembe
Filing Documents
- ea0221909-8ka3_aditxt.htm (8-K/A) — 37KB
- ea022190901ex99-1_aditxt.htm (EX-99.1) — 249KB
- ea022190901ex99-2_aditxt.htm (EX-99.2) — 539KB
- 0001213900-24-100993.txt ( ) — 1071KB
- adtx-20240401.xsd (EX-101.SCH) — 3KB
- adtx-20240401_lab.xml (EX-101.LAB) — 33KB
- adtx-20240401_pre.xml (EX-101.PRE) — 22KB
- ea0221909-8ka3_aditxt_htm.xml (XML) — 9KB
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (a) Financial statements of business or funds acquired. The (i) unaudited condensed consolidated statements of financial position of Appili as of September 30, 2024 and 2023, and the related unaudited condensed consolidated 2024 are filed as Exhibit 99.1 hereto and are incorporated herein by reference. (b) Pro forma financial information. The unaudited pro forma consolidated financial information of the Company giving pro forma effect to the acquisitions of Evofem Biosciences, Inc. and Appili, (for more information about the Evofem Biosciences, Inc. acquisition, please see our separate 8K filed with the SEC on November 21, 2024) consisting of the unaudited pro forma consolidated ended September 30, 2024, are filed as Exhibit 99.2, hereto and are incorporated herein by reference. (d) Exhibits. Exhibit No. Exhibit 99.1 Unaudited condensed consolidated financial statements of Appili Therapeutics, Inc. as of and for the six months ended September 30, 2024 and 2023 99.2 Unaudited pro forma consolidated financial information as of and for the nine months ended September 30, 2024 104 Cover Page Interactive Data File (embedded within the XBRL document) -2-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ADITXT, INC. Date: November 21, 2024 By: /s/ Amro Albanna Amro Albanna Chief Executive Officer -3-